Glimepirid Stada (Glimepiride)

Glimepirid Stada is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It is typically used when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be combined with metformin or other oral antidiabetic agents.
• May be prescribed for patients who have not achieved target HbA1c with lifestyle changes alone.
• Used as an adjunct to diet and exercise to maintain long‑term glucose control.
• Suitable for adult patients with established type 2 diabetes.

Glimepirid Stada may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common

• Hypoglycemia (low blood sugar)
• Headache
• Dizziness
• Nausea or gastrointestinal upset
• Weight gain
• Skin rash or itching

Serious

• Severe hypoglycemia with loss of consciousness
• Allergic reactions such as swelling of the face, lips, or throat
• Hepatotoxicity (liver injury)
• Hematologic abnormalities like leukopenia or thrombocytopenia

Before starting Glimepirid Stada, patients should consider several safety factors to reduce the risk of complications.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Review history of hypoglycemia or episodes of severe low blood sugar.
• Use caution in elderly patients who may be more sensitive to glucose fluctuations.
• Monitor blood glucose regularly to adjust dosage as needed.
• Discuss pregnancy or breastfeeding plans with a healthcare provider, as safety data are limited.
• Avoid abrupt discontinuation without medical guidance to prevent rebound hyperglycemia.

Glimepirid Stada can interact with other medicines, influencing its effectiveness or increasing the risk of adverse effects.

Avoid

• Other sulfonylureas or insulin, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride levels.
• MAO‑B inhibitors, which may potentiate hypoglycemic response.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function.
• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may alter blood glucose control.
• Antidepressants such as SSRIs, which have been reported to affect glycemic regulation.